Merck Millipore Granted Patent for Selective Layering Method that Sets Standard for Consistency of Virus Filtration Performance
Merck Millipore, the Life Science division of Merck, has been granted a US patent for developing a selective layering method that significantly improves the consistency of virus filtration performance. The method is used to manufacture Merck Millipore's Viresolve Pro Device, a virus filtration technology that offers highly productive parvovirus clearance for monoclonal antibodies and therapeutic proteins. As a result of selective layering, the Viresolve Pro Device provides an industry-leading performance consistency superior to other virus filtration devices currently on the market.
The Viresolve Pro Device uses a dual-layer PES membrane designed to simultaneously deliver high parvovirus log reduction value (LRV), capacity and flux. Using the now patented method, the top and bottom membrane layers are selected from different segments of the normal membrane population and optimally paired to drive performance consistency. This optimal pairing strategy reduces device-to-device throughput performance variability by about half compared to random pairing, while also increasing the average throughput performance. The result is strong batch-to-batch consistency in virus retention, permeability and throughput capacity.
"This new patent reflects Merck Millipore's ongoing commitment to delivering innovation to our customers in biopharmaceutical manufacturing," said Udit Batra, President and CEO of Merck Millipore. "Our team of experts developed this methodology to significantly improve upon industry standards for virus clearance unit operations. The resulting performance consistency enables drug manufacturers to accelerate the process of developing drug therapies for patients in need."
Introduced in 2008, the Viresolve Pro Device has been proven to enable robust parvovirus clearance and a highly productive virus filtration unit operation. The device offers high mass capacity, as well as optional capacity enhancement with the use of an adsorptive polishing step. In addition, its single-use flowpaths require no cleaning validation and the processing typically takes less than four hours at scale, making the device quick and easy to install and use.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.